Payment overview · 2025
General Payments
$14,623.81
32 reported records · 14 companies
Healthcare provider profile · identity verified
Christopher M Wilson, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · AVON, IN · NPI 1467553149
Verified facts
What the public records show
CMS Open Payments records show Christopher M Wilson, MD received $14,623.81 in general payments during 2025 across 32 reported records.
Genentech USA, Inc. accounted for 89.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ubrelvy by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $13,082.63 | 89.5% | 9 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $327.72 | 2.2% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $302.88 | 2.1% | 4 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $238.56 | 1.6% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $150.00 | 1.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $133.00 | 0.9% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $108.08 | 0.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $72.00 | 0.5% | 3 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $48.33 | 0.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $47.42 | 0.3% | 3 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $45.00 | 0.3% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $31.39 | 0.2% | 1 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $22.22 | 0.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.58 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,500.00 | 3 |
| Food and Beverage | $1,534.21 | 25 |
| Travel and Lodging | $439.60 | 3 |
| Consulting Fee | $150.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $13,082.63 | 9 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $13,082.63 | 9 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $327.72 | 3 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $238.56 | 2 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $133.00 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $113.05 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $113.05 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $108.08 | 1 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $76.78 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $72.00 | 3 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $48.33 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $47.42 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $45.00 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $31.39 | 1 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 326 | 110 |
| Memantine Hcl | Memantine Hcl | 250 | 80 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 234 | 67 |
| Gabapentin | Gabapentin | 216 | 73 |
| Topiramate | Topiramate | 210 | 55 |
| Pregabalin | Pregabalin | 175 | 48 |
| Levetiracetam | Levetiracetam | 172 | 43 |
| Clonazepam | Clonazepam | 133 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 120 | 37 |
| Zonisamide | Zonisamide | 116 | 30 |
| Primidone | Primidone | 108 | 35 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 93 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 26 |
| Mirtazapine | Mirtazapine | 83 | 21 |
| Baclofen | Baclofen | 82 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 18 |
| Lamotrigine | Lamotrigine | 72 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 70 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 66 | 23 |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 63 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 16 |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 56 | suppressed |
| Lacosamide | Lacosamide | 52 | 13 |
| Prednisone | Prednisone | 51 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 49 | 11 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 49 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | 16 |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 38 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 36 | suppressed |
| Alprazolam | Alprazolam | 33 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 32 | suppressed |
| Diazepam | Diazepam | 32 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 32 | suppressed |
| Rivastigmine | Rivastigmine | 32 | 12 |
| Aimovig Autoinjector | Erenumab-Aooe | 29 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 29 | 12 |
| Rasagiline Mesylate | Rasagiline Mesylate | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 26 | suppressed |
| Dalfampridine Er | Dalfampridine | 25 | suppressed |
| Gocovri | Amantadine Hcl | 25 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 25 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 25 | suppressed |
| Ubrelvy | Ubrogepant | 25 | suppressed |
| Amantadine | Amantadine Hcl | 24 | suppressed |
| Entacapone | Entacapone | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 22 | suppressed |
| Briviact | Brivaracetam | 21 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 21 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 20 | suppressed |
| Teriflunomide | Teriflunomide | 20 | suppressed |
| Lorazepam | Lorazepam | 19 | 13 |
| Rytary | Carbidopa/Levodopa | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Qulipta | Atogepant | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Xadago | Safinamide Mesylate | 17 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Levetiracetam Er | Levetiracetam | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Xcopri | Cenobamate | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 13 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 13 | suppressed |
| Rebif Rebidose | Interferon Beta-1a/Albumin | 13 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Clobazam | Clobazam | 11 | suppressed |
| Cuvitru | Immun Glob G(Igg)/Gly/Iga Ov50 | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Keppra | Levetiracetam | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $14,623.81 · 32 records | Genentech USA, Inc. | BRIUMVI, Dexcom G6 Transmitter, INSPIRE, Mavenclad, Nayzilam, Ocrevus, Ocrevus Zunovo, Restrata Wound Matrix, Rystiggo, TYSABRI, The Cologuard Plus Collection Kit, ULTOMIRIS, UPLIZNA, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VYALEV, VYVGART, Zilbrysq | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error